

Datasheet: HCA216P BATCH NUMBER INN1702

Description:	HUMAN ANTI INFLIXIMAB:HRP		
Specificity:	INFLIXIMAB		
Other names:	REMICADE®		
Format:	HRP		
Product Type:	Monoclonal Antibody		
Clone:	AbD19376_hlgG1		
Isotype:	lgG1		
Quantity:	0.1 mg		

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .						
	Yes No Not Determined Suggested Dilution						
	ELISA •						
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.						
Product Form	Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.						
Preparation	Purified IgG prepared by affinity chromatography on Protein A						
Buffer Solution	Phosphate buffered saline						
Preservative Stabilisers	0.01% Thiomersal						
Approx. Protein Concentrations	Total protein concentration 0.1 mg/ml						
Immunogen	Infliximab						
Specificity	Human anti Infliximab, clone AbD19376_hIgG1, is an anti-idiotypic antibody that binds						

	to both free infliximab and to infliximab bound to its target, TNFα. Clone AbD19376_hlgG1 does not inhibit the binding of infliximab to TNFα. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.				
	Clone AbD19376_hIgG1 binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab but not rituximab.				
	Human anti Infliximab, clone AbD19376_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD19376_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays to measure total infliximab levels (free drug, partially bound and fully bound).				
	Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.				
	Infliximab is directed against Tumor Necrosis Factor Alpha (TNF α) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF α expressing T-lymphocytes.				
	View a summary of all anti-infliximab antibodies.				
Affinity	The monovalent intrinsic affinity of this antibody in an unconjugated format was measured as K _D =0.7 nM by real time, label-free molecular interaction analysis on immobilized infliximab.				
ELISA	This product may be used as a detection reagent in a bridging ELISA for PK assay development together with <u>HCA214</u> or <u>HCA212</u> as the capture reagent. Protocol: <u>PK bridging ELISA to measure total drug</u>				
References	1. Kashiwagi, N. <i>et al.</i> (0) Method for measuring anti-drug antibody <u>US Patent Application</u> <u>US2017315118A1</u>				
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.				
Guarantee	12 months from date of despatch				
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp &				

	Dohme Corp.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA216P 10094
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>

Related Products

Recommended Useful Reagents

HUMAN ANTI INFLIXIMAB (HCA212) HUMAN ANTI INFLIXIMAB (HCA214) HISPEC ASSAY DILUENT (BUF049A) RECOMBINANT HUMAN TNF ALPHA (PHP051)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-rad.com		Email: antibody_sales_uk@bio-rad.com		Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M371641:200612'

Printed on 01 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint